Solara Active Pharma Sciences Ltd (NSE:SOLARAPP1)

Q3 2026 Solara Active Pharma Sciences Ltd Earnings Call Transcript

Feb 6, 2026 / 10:00 AM GMT

Release Date Price: ₹267.45

Transcript

Key Points

Positve

The non-ibuprofen business of Solara Active Pharma Sciences Ltd (BOM:541540) is showing strong performance with a gross margin of 56% and an EBITDA margin of 25%, which is at the higher end of the industry range for API businesses.
The company has achieved a 10% quarter-over-quarter revenue growth, indicating positive momentum in its growth business.
Solara Active Pharma Sciences Ltd (BOM:541540) has reduced its debt by 19%, demonstrating effective financial management and operational cash flow generation.
The growth API business, which includes ibuprofen derivatives, is operating at a high gross margin of over 55%, reinforcing the company's strategic pivot towards more profitable segments.
The company is focusing on operational efficiencies and cost leverage to improve margins and maintain a healthy balance sheet, which is crucial for long-term sustainability.

Negative

The ibuprofen business is facing significant challenges due to excess capacities and newer technologies, resulting in lower realizations and depressed profitability.
Solara Active Pharma Sciences Ltd (BOM:541540) is experiencing pricing pressures in its ibuprofen segment, which has been a drag on overall financial performance.
The company has mothballed its Vizag plant due to underutilization and is facing difficulties in selling its full ibuprofen capacity.
Gross margins have decreased by 386 basis points quarter-over-quarter, primarily due to headwinds in the ibuprofen-based business.
There is uncertainty regarding the future of the ibuprofen business, with strategic options still under evaluation, which may impact the company's short-term financial stability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SOLA.NS - Solara Active Pharma Sciences Ltd
Q3 2026 Solara Active Pharma Sciences Ltd Earnings Call
Feb 06, 2026 / 10:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
And welcome to the Solara Active Pharma Science Lim, Ffi 26 earning conference score.

All participant line will be theli for you to ask questions after the presentation conclude, Should he need assisttain during the conference call, please signal an operator by pressing Star, then 0 on your touchstone forward.

I now had the conference over to Mr. Bhishek.

Thank you and over to you, sir.

Very good afternoon and thank you for joining us today for Solara earnings call, for the 3rd quarter and 9th month in a financial year 2026.

Today we have with us a Arun, founder and non-director, Sandeep Md and CEO, and Sharat, CFO of the company, to share the hala of the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.